GRAIL, Inc. $GRAL Shares Purchased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. boosted its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 18.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 68,577 shares of the company’s stock after purchasing an additional 10,565 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in GRAIL were worth $5,870,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Osbon Capital Management LLC purchased a new stake in GRAIL during the 4th quarter worth about $51,000. Fund Advisors of America Inc FL purchased a new position in shares of GRAIL in the 4th quarter valued at about $299,000. DUTCH ASSET Corp purchased a new position in shares of GRAIL in the 4th quarter valued at about $532,000. Corient Private Wealth LLC raised its position in shares of GRAIL by 60.4% during the 4th quarter. Corient Private Wealth LLC now owns 9,274 shares of the company’s stock worth $794,000 after acquiring an additional 3,491 shares in the last quarter. Finally, NWF Advisory Services Inc. raised its position in shares of GRAIL by 7.6% during the 4th quarter. NWF Advisory Services Inc. now owns 22,070 shares of the company’s stock worth $1,889,000 after acquiring an additional 1,564 shares in the last quarter.

Insider Transactions at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 232,464 shares of company stock worth $11,621,242 in the last three months. Corporate insiders own 1.83% of the company’s stock.

GRAIL Stock Performance

GRAIL stock opened at $65.92 on Friday. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The company has a market capitalization of $2.83 billion, a P/E ratio of -6.36 and a beta of 3.15. The stock has a 50-day simple moving average of $60.67 and a 200-day simple moving average of $71.58.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. As a group, analysts forecast that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on GRAL. Wolfe Research began coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Mizuho started coverage on shares of GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective on the stock. Guggenheim reduced their price objective on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research report on Monday, March 30th. The Goldman Sachs Group began coverage on shares of GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $67.00.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL completed a $110 million equity financing with Samsung affiliates, adding capital that could support operations and reduce near-term financing pressure. GRAIL Completes $110 Million Equity Financing With Samsung Entities
• Neutral Sentiment: Multiple law firms issued notices and deadline reminders about an already-filed securities class action, including a lead-plaintiff deadline of August 4, 2026. ROSEN, LEADING TRIAL LAWYERS, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL
• Neutral Sentiment: Short-interest data was reported with no meaningful shares outstanding, offering little new signal for trading direction.
• Negative Sentiment: Several firms announced or promoted class-action litigation alleging investors were harmed by GRAIL’s disclosures around the NHS-Galleri trial failure, reinforcing legal overhang and potential damages risk. GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout — HBSS

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.